Circulating soluble fas ligand correlates with disease activity in Graves' hyperthyroidism

Metabolism: Clinical and Experimental

Volumn 51, Issue 6, 2002, Pages 769-773

  Wang, Chih Yuan ^a   Zhong, Wen Bin ^a   Chang, Tien Chun ^a   Tsai, Yuan Feen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BIOCHEMICAL MARKER; CELL MEMBRANE PROTEIN; FAS ANTIGEN; FAS LIGAND; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXICITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; LIGAND BINDING; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REMISSION;

EID: 0036281791     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.32034     Document Type: Article

References (28)

1. Apoptosis and thyroiditis
2. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
3. Functional fas ligand expression in thyrocytes from patients with Graves' disease
4. Fas ligand expression in the thyroid carcinoma: A potential mechanism of immune evasion
5. Constitutive expression of FasL in thyrocytes
6. Editorial: Dying (apoptosing?) for a consensus on the Fas death pathway in the thyroid
7. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
8. Metalloproteinase-mediated release of human Fas ligand
9. Expression of the functional soluble form of human Fas ligand in activated lymphocytes
10. Fas ligand in human serum
11. Pathology of thyroid disease
12. Modulation of Fas-mediated apoptosis of human thyroid epithelial cells by IgG from patients with Grave's disease (GD) and idiopathic myxoedema
13. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases
14. Increased serum soluble Fas in patients with Grave's disease
15. The Fas death factor
16. Differential activity of soluble versus cellular Fas ligand: Regulation by an accessory molecule
17. Soluble Fas ligand induces epithelial cell apoptosis in human with acute lung injury (ARDS)
18. Levels of soluble Fas ligand in myocarditis
19. Elevated circulating and cardiac secretion of soluble Fas ligand in patients with congestive heart failure
20. Fas ligand-induced apoptosis as a mechanism of immune privilege
21. A role for CD95 ligand in preventing graft rejection
22. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis
23. Gene therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for Fas ligand
24. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
25. Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice
26. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells
27. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor
28. Increased serum soluble Fas ligand in hyperthyroid Graves' disease